News MSD adds bispecific cancer antibody via $1.3bn Curon deal MSD has an extensive pipeline in oncology but hasn't been a player in bispecific antibodies.
News Ipsen charts $1.75bn course for Kartos acquisition Ipsen has agreed to buy cancer biotech Kartos Therapeutics for $450m upfront, adding a late-stage drug in the challenging MDM2 inhibitor class.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
